Neglected Diseases

Neglected Diseases, particularly Neglected Tropical Diseases (NTDs) as defined by the World Health Organization (WHO), are a diverse group of communicable diseases prevalent in tropical and subtropical conditions in 149 countries. They are intrinsically linked to poverty and thrive in areas with inadequate sanitation and healthcare access. In enterprise risk management, this concept is a critical regulatory and economic classification. For instance, Section 524 of the U.S. Food, Drug, and Cosmetic (FD&C) Act specifically defines "neglected tropical disease" to incentivize drug development through programs like the Priority Review Voucher (PRV). This distinguishes them from "orphan drugs," which are for rare diseases regardless of geography or economic context, whereas neglected diseases are defined by their association with poverty and market failure.

In the pharmaceutical and biotech sectors, applying the concept of neglected diseases involves strategically integrating it into R&D and regulatory affairs to acquire high-value assets. Key steps include: 1. **Opportunity Scanning & Risk Assessment:** Monitor WHO and FDA lists of neglected diseases and assess the internal R&D pipeline for potential candidates. This includes evaluating clinical trial feasibility, geopolitical risks, and reputational benefits. 2. **Regulatory Pathway Planning:** For a selected candidate, develop a detailed strategy to meet the criteria for a PRV under Section 524 of the FD&C Act. 3. **Asset Monetization:** Upon receiving a PRV, decide whether to use it to expedite a blockbuster drug's review or sell it. Novartis, for example, has successfully obtained and utilized PRVs. Measurable outcomes include the sale price of a PRV (historically up to $125 million), reduced review time for a priority drug, and improved ESG ratings.

Taiwanese enterprises face three primary challenges when pursuing drug development for neglected diseases: 1. **High R&D Costs & Market Failure:** The immense cost of drug development is difficult to recoup from target populations with low purchasing power. 2. **Unfamiliar Regulatory Pathways:** Navigating the specific U.S. FDA requirements for the PRV program under Section 524 of the FD&C Act requires specialized expertise that may be lacking. 3. **Complex International Clinical Trials:** Conducting trials in endemic developing countries presents significant logistical, ethical, and operational hurdles. To overcome these, companies should pursue Public-Private Partnerships (PPPs) with NGOs (e.g., DNDi) to share costs, engage expert consultants for FDA navigation, and repurpose existing technology platforms to reduce initial investment.

Winners Consulting specializes in neglected diseases for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact